---
title: "Ocular Therapeutix grants new SVP inducement awards of 85,000 stock options, 28,000 RSUs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290473337.md"
description: "Ocular Therapeutix granted inducement equity awards to new SVP Kelley Allison, effective June 15, 2026. The package includes 85,000 non-statutory stock options priced at $8.99, vesting over four years, and 28,000 restricted stock units (RSUs), vesting annually over three years."
datetime: "2026-06-22T20:05:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290473337.md)
  - [en](https://longbridge.com/en/news/290473337.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290473337.md)
---

# Ocular Therapeutix grants new SVP inducement awards of 85,000 stock options, 28,000 RSUs

-   Ocular Therapeutix granted inducement equity awards to new SVP, Market Access and Health Policy Kelley Allison, effective June 15, 2026. \* Award includes a non-statutory stock option for 85,000 shares priced at USD 8.99, matching the stock’s Nasdaq close on grant date. \* Option runs 10 years; vests over four years with 25% at year one, then monthly over the next three years. \* Grant also includes restricted stock units for 28,000 shares; vests in equal annual installments over three years. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocular Therapeutix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606221605PRIMZONEFULLFEED9750634) on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [OCUL.US](https://longbridge.com/en/quote/OCUL.US.md)

## Related News & Research

- [Ocular Therapeutix grants new SVP Beth Rada options for 85,000 shares, 28,000 RSUs under inducement plan](https://longbridge.com/en/news/295840860.md)
- [Ocular Therapeutix Faces Governance and Perception Risks from Insider Equity Compensation and Trading Practices](https://longbridge.com/en/news/294775792.md)
- [Elkem terminates share option program, cancels 5,017,333 outstanding options](https://longbridge.com/en/news/295490899.md)
- [Oric Pharma grants 125,400 stock options, 20,550 RSUs to five new employees](https://longbridge.com/en/news/295275271.md)
- [Arcutis Biotherapeutics grants 143,500 RSUs, 37,000 stock options to new hires under inducement plan](https://longbridge.com/en/news/295272046.md)